HK Stock Market Move | ZHAOKE OPHTH-B(06622) rose nearly 4%, core product NVK002 simplified new drug application recently received acceptance.
With the close, Mega Medical Ophthalmology-B (06622) rose nearly 4%, rising by 3.88% to 1.34 Hong Kong dollars, with a turnover of 2.86 million Hong Kong dollars.
ZHAOKE OPHTH-B(06622) rose by nearly 4%, reaching 3.88% at the time of publication, at 1.34 Hong Kong dollars, with a turnover of 2.86 million Hong Kong dollars.
On the news front, ZHAOKE OPHTH-B recently announced that the National Medical Products Administration has officially accepted the company's application for a new drug for NVK002 (0.01% low-dose atropine). NVK002 is one of the company's most promising core drugs, used to control the progression of myopia in children and adolescents. The application for the new drug for NVK002 is based on Phase III clinical trials conducted by ZHAOKE OPHTH-B in China. It is worth mentioning that currently, the only atropine sulfate eye drops available in China are the Xingqi Meio brand from Shenyang Xingqi Pharmaceutical, which was approved on March 11, 2024.
Related Articles
Renhe (000650.SZ) partners with Huajian (01931): Listed companies enter the field, who can be the first to cut the big cake of RWA?
Moody's Corporation warns of a $300 billion AI deal risk for Oracle Corporation (ORCL.US) and maintains its Baa2 rating unchanged.
PayPal (PYPL.US) teams up with Alphabet Inc. Class C (GOOGL.US)! The "AI autonomous payment model" is becoming a reality.
Renhe (000650.SZ) partners with Huajian (01931): Listed companies enter the field, who can be the first to cut the big cake of RWA?
Moody's Corporation warns of a $300 billion AI deal risk for Oracle Corporation (ORCL.US) and maintains its Baa2 rating unchanged.
PayPal (PYPL.US) teams up with Alphabet Inc. Class C (GOOGL.US)! The "AI autonomous payment model" is becoming a reality.
